Stock BPTH BIO-PATH HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Bio-Path Holdings, Inc.

Equities

BPTH

US09057N4097

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.68 USD +1.71% Intraday chart for Bio-Path Holdings, Inc. -37.53% -71.06%
Apr. 19 Bio-Path Closes $1.2 Million Share Offering MT
Apr. 18 Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients CI

Evolution of the average Target Price on Bio-Path Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9840fa4bb0004b84692ea02e889.GoK9aubM0ttiIR8Yu7Dcxyeh1PMB7pGEB30-DqdmoaQ.IuH7IJa-5pdRcVh-z9WelWT4k7Rt2sHqSDdVT_IHyO4otPIYtriIkCpZLw~a8059243f3a899f540dbb45e721f04d5

Analyst Recommendations on Bio-Path Holdings, Inc.

HC Wainwright Adjusts Price Target on Bio-Path Holdings to $9 From $12, Reiterates Buy Rating MT
BIO PATH : HC Wainwright Adjusts Price Target on Bio-Path Holdings to $12 From $10, Maintains Buy Rating MT
BIO PATH : Roth Capital Starts Bio-Path Holdings at Buy With $13 Price Target MT
BIO PATH : HC Wainwright Adjusts Bio-Path Holdings' Price Target to $10 from $12, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.68 USD
Average target price
40 USD
Spread / Average Target
+1,392.54%
High Price Target
40 USD
Spread / Highest target
+1,392.54%
Low Price Target
40 USD
Spread / Lowest Target
+1,392.54%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bio-Path Holdings, Inc.

HC Wainwright
Roth Capital Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BPTH Stock
  4. Consensus Bio-Path Holdings, Inc.